• Akutsu, M., Suzuki, K., Tsunoda, S. & Kano, Y. (1996) Effects of carboplatin combination with etoposide against leukemia/lymphoma cell lines. Gan To Kagaku Ryoho, 23, 297302.
  • Bishop, J.F., Raghavan, D., Stuart-Harris, R., Morstyn, G., Aroney, R., Kefford, R., Yuen, K., Lee, J., Gianoutsos, P., Olver, I.N., Zalcberg, J., Ball, D., Bull, C. & Fox, R. (1987) Carboplatin (CBCDA, JM-8) and VP-16-213 in previously untreated patients with small-cell lung cancer. Journal of Clinical Oncology, 10, 15741578.
  • Cortelazzo, S., Rambaldi, A., Rossi, A., Oldani, E., Ghielmini, M., Benedetti, F., Tarella, C., Zaglio, F., Vitolo, U., Di Nicola, M., Pogliani, E., Cavalli, F., Gianni, A.M. & Barbui, T. (2001) Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non-Hodgkin's lymphoma. British Journal of Haematology, 114, 333341.
  • Davis, C.L. (2001) Interferon and cytotoxic chemotherapy for the treatment of post-transplant lymphoproliferative disorder. Transplant Infectious Disease, 3, 108118.
  • Drewinko, B. & Barlogie, B. (1976) Survival and cycle-progression delay of human lymphoma cells in vitro exposed to VP-16-213. Cancer Treatment Reports, 60, 12951306.
  • Duffull, S.B. & Robinson, B.A. (1997) Clinical pharmacokinetics and dose optimisation of carboplatin. Clinical Pharmacokinetics, 33, 161183.
  • Eiermann, W., Achterrath, W., Lenaz, L. & Hepp, H. (1991) Carboplatin/etoposide as first-line chemotherapy in advance ovarian carcinoma: a pilot study. Cancer Chemtherapy and Pharmacology, 27, 389393.
  • Garrett, T.J., Chadburn, A., Barr, M.L., Drusin, R.E., Chen, J.M., Schulman, L.L., Smith, C.R., Reison, D.S., Rose, E.A., Michler, R.E. & Knowles, D.M. (1993) Post-transplant lymphoproliferative disorders treated with cyclophosphamid–doxorubicin–vincristine–prednisone chemotherapy. Cancer, 72, 27822785.
  • Haddad, E., Paczesny, S., Leblond, V., Seigneurin, J.M., Stern, M., Achkar, A., Bauwens, M., Delwail, V., Debray, D., Duvoux, C., Hubert, P., de Ligny, B.H., Wijdenes, J., Durandy, A. & Fischer, A. (2001) Treatment of B-lymphoproliferative disorders with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1–2 clinical trial. Blood, 97, 15901597.
  • Harris, N.L., Swerdlow, S.H., Frizzera, G. & Knowles, D.M. (2001) Post-transplant lymphoproliferative disorders. In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues (ed. by E.S.Jaffe, N.L.Harris, H.Stein & J.W.Vardlman), pp. 264269. IARC Press, Cheennra.
  • Joel, S.P., Shah, R., Clark, P.I. & Slevin M.L. (1996) Predicting etoposide toxicity: relationship to organ function and protein binding. Journal of Clinical Oncology, 14, 257267.
  • Klastersky, J. (1988) Cisplatin and carboplatin in combination with etoposide as treatment for non-small cell lung cancer: the experience of the EORTC Lung Cancer Working Party. Cancer Treatment Revues, 15, 3340.
  • Kushner, B.H., Kwon, J.H., Gulati, S.C. & Castro-Malspina, H. (1987) Preclinical assessment of purging with VP-16-213: key role for long-term marrow cultures. Blood, 69, 6571.
  • Mentzer, S.J., Fingerroth, J. & Reilly, J.J. (1998) Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr virus-associated lymphoma. Blood Cell, Molecules and Diseases, 30, 114123.
  • Miller, A.B., Hoogstraten, B., Staquet, M. & Winkler, A. (1981) Reporting results of cancer treatment. Cancer, 47, 207214.
  • Milpied, N., Vasseur, B., Parquet, N., Garnier, J.L., Antoine, C., Quartier, P., Carret, A.S., Bouscary, D., Faye, A., Bourbigot, B., Reguerre, Y., Stoppa, A.M., Bourquard, P., Hurault de Ligny, B., Dubief, F., Mathieu-Boue, A. & Leblond, V. (2000) Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Annals of Oncology, 11(Suppl. 1), 113116.
  • Oertel, S.H., Ruhnke, M.S., Anagnostopoulos, I., Kahl, A.A., Frewer, A.F., Bechstein, W.O., Hummel, M.W. & Riess, H.B. (1999) Treatment of Epstein-Barr virus-induced Post-transplant lymphoproliferative disorder (PT-LPD) with Foscarnet alone in an adult after simultaneous heart and renal transplantation. Transplantation, 67, 765767.
  • Oertel, S.H., Anagnostopoulos, I., Bechstein, W.O., Liehr, H. & Riess, H.B. (2000) Treatment of post-transplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation: a new drug in therapy of patients with PT-LPD after solid organ transplantation? Transplantation, 69, 430432.
  • Oertel, S.H., Anagnostopoulos, I., Hummel, M., Jonas, S. & Riess, H.B. (2002) Identification of early antigen BZLF1/ZEBRA protein of Epstein-Barr virus can predict the effectiveness of antiviral treatment in patients with post-transplant lymphoproliferative disease. British Journal of Haematology, 118, 11201123.
  • Olyaei, A.J., de Mattos, A.M. & Bennett, W.M. (1999) Immunosuppressant-induced nephropathy: pathophysiology, incidence and management. Drug Safety, 21, 471488.
  • Penn, I., Hammond, W., Brettschneider, L. & Starzl, T.E. (1969) Malignant lymphomas in transplantation patients. Transplantation Proceedings, 1, 106112.
  • Scott, J.P. & Higenbottam, T.W. (1988) Adverse reactions and dinteractions of cyclosporin. Medical Toxicology and Adverse Drug Experience, 3, 107127.
  • Starzl, T.E., Nalesnik, M.A., Porter, K.A., Ho, M., Iwatsuki, S., Griffith, B.P., Rosenthal, J.T., Hakala, T.R., Shaw, Jr, B.W., Hardesty, R.L., Jaffe, R. & Bahnson, H.T. (1984) Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin – steroid therapy. Lancet, 1, 583587.
  • Young, L., Alfieri, C., Hennessy, K., Evans, H., O'Hara, C., Anderson, K.C., Ritz, J., Shapiro, R.S., Rickinson, A., Kieff, E. & Cohen, J.I. (1989) Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. New England Journal of Medicine, 321, 10801085.